Is taxane/platinum/5 fluorouracil superior to taxane/platinum alone and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers?
Cisplatin and 5 fluorouracil drug combination is inferior to the combination of taxane with these 2 drugs. However, often in clinical practice at our center giving TPF (docetaxel, cisplatin, 5 fluorouracil) is difficult in view of logistics and tolerance issues. In such a scenario, we prefer to use...
Gespeichert in:
| Veröffentlicht in: | Indian journal of cancer 2015-01, Vol.52 (1), p.70 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 70 |
| container_title | Indian journal of cancer |
| container_volume | 52 |
| creator | Noronha, V Patil, V Joshi, A Muddu, V Bhattacharjee, A Juvekar, S Arya, S Chaturvedi, P Chaukar, D Pai, P S Dcruz, A K Prabhash, K |
| description | Cisplatin and 5 fluorouracil drug combination is inferior to the combination of taxane with these 2 drugs. However, often in clinical practice at our center giving TPF (docetaxel, cisplatin, 5 fluorouracil) is difficult in view of logistics and tolerance issues. In such a scenario, we prefer to use the 2 drugs combination of platinum and taxane. However, no study has addressed whether a 2 drugs combination, which includes taxane is inferior to the 3 drugs combination and which the taxane of choice is in the 2 drugs combination of taxane and platinum.
This is a retrospective analysis of prospectively collected data of patients undergoing induction chemotherapy (IC) in oral cavity cancers from 2010 to 2012. We chose for analysis those patients who had a baseline scan done within 4 weeks of starting therapy and a follow-up scan done within 2 weeks of completion of the second cycle of IC. Response was scored in accordance with RECIST version 1.1. Chi-square analysis was done to compare response rates (RRs) between regimens.
Two hundred and forty-five patients were identified. The median age was 45 years (24-70 years), 208 (84.9%) were male patients, and 154 patients (62.9%) had primary in the Buccal mucosa. The regimens received were TPF 22 (9%), docetaxel + cisplatin 97 (39.6%), paclitaxel + cisplatin 89 (36.3%), docetaxel + carboplatin 16 (6.5%) and paclitaxel + carboplatin 21 (8.6%). The overall RRs were complete response, partial response, stable disease and progressive disease in 4 (1.6%), 56 (22.9%), 145 (59.2%) and 40 (16.3%). The 3 drugs regimen (TPF) had 50% RR as compared to 22% RR with 2 drugs regimen (P = 0.004). Docetaxel containing regimens had 30.3% RR as compared to 17.2% RR with paclitaxel containing regimens (P = 0.094).
TPF has better RR than a 2 drugs taxane-containing regimen and docetaxel leads to a better RR than paclitaxel for IC in locally advanced oral cavity cancers. |
| doi_str_mv | 10.4103/0019-509X.175604 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_1771741364</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A442758941</galeid><sourcerecordid>A442758941</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-d8ea34d0533befea313ace390d885ee5199b91febf38efc6ff29038d665fe8fc3</originalsourceid><addsrcrecordid>eNptklFrHCEUhaW0NNtt3_tUhELfZldHZ0afSghNGwj0pYW-Da5eswZnnKoTun-ovzMOm6ZNWRSvXL-jeDgIvaVkwylhW0KorBoif2xo17SEP0MrKqWoeNfx52j1eHyGXqV0S0jNai5eorO6FayTnVyh31cJZ_VLjbCdvMpunIdtg62fQwxzVNp5nOYJogsR5_A_ipUPI2A1GmwCpLJoKAh4nOM8THhS2rtjw41lmllnF0ac9xDVdMC23OqDVt4fsDJ3atRgcIjKY63uXD6UUloxfXyNXljlE7x5qGv0_fLTt4sv1fXXz1cX59eV5i3LlRGgGDekYWwHtuwpUxqYJEaIBqAp5uwktbCzTIDVrbW1JEyYtm0sCKvZGr0_3jvF8HOGlPvbYsNYnuxp19GOU9byv9SN8tC70YZcrBpc0v0553XXCFnANapOUDcwlr8vtllX2k_4zQm-DAOD0ycFH_4R7EH5vE_Bz4vF6SlIjqCOIaUItp-iG1Q89JT0S5D6JSn9kpT-GKQiefdgxLwbwDwK_iSH3QPt6MWz</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1771741364</pqid></control><display><type>article</type><title>Is taxane/platinum/5 fluorouracil superior to taxane/platinum alone and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers?</title><source>MEDLINE</source><source>Medknow Open Access Medical Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Bioline International</source><creator>Noronha, V ; Patil, V ; Joshi, A ; Muddu, V ; Bhattacharjee, A ; Juvekar, S ; Arya, S ; Chaturvedi, P ; Chaukar, D ; Pai, P S ; Dcruz, A K ; Prabhash, K</creator><creatorcontrib>Noronha, V ; Patil, V ; Joshi, A ; Muddu, V ; Bhattacharjee, A ; Juvekar, S ; Arya, S ; Chaturvedi, P ; Chaukar, D ; Pai, P S ; Dcruz, A K ; Prabhash, K</creatorcontrib><description>Cisplatin and 5 fluorouracil drug combination is inferior to the combination of taxane with these 2 drugs. However, often in clinical practice at our center giving TPF (docetaxel, cisplatin, 5 fluorouracil) is difficult in view of logistics and tolerance issues. In such a scenario, we prefer to use the 2 drugs combination of platinum and taxane. However, no study has addressed whether a 2 drugs combination, which includes taxane is inferior to the 3 drugs combination and which the taxane of choice is in the 2 drugs combination of taxane and platinum.
This is a retrospective analysis of prospectively collected data of patients undergoing induction chemotherapy (IC) in oral cavity cancers from 2010 to 2012. We chose for analysis those patients who had a baseline scan done within 4 weeks of starting therapy and a follow-up scan done within 2 weeks of completion of the second cycle of IC. Response was scored in accordance with RECIST version 1.1. Chi-square analysis was done to compare response rates (RRs) between regimens.
Two hundred and forty-five patients were identified. The median age was 45 years (24-70 years), 208 (84.9%) were male patients, and 154 patients (62.9%) had primary in the Buccal mucosa. The regimens received were TPF 22 (9%), docetaxel + cisplatin 97 (39.6%), paclitaxel + cisplatin 89 (36.3%), docetaxel + carboplatin 16 (6.5%) and paclitaxel + carboplatin 21 (8.6%). The overall RRs were complete response, partial response, stable disease and progressive disease in 4 (1.6%), 56 (22.9%), 145 (59.2%) and 40 (16.3%). The 3 drugs regimen (TPF) had 50% RR as compared to 22% RR with 2 drugs regimen (P = 0.004). Docetaxel containing regimens had 30.3% RR as compared to 17.2% RR with paclitaxel containing regimens (P = 0.094).
TPF has better RR than a 2 drugs taxane-containing regimen and docetaxel leads to a better RR than paclitaxel for IC in locally advanced oral cavity cancers.</description><identifier>ISSN: 0019-509X</identifier><identifier>EISSN: 1998-4774</identifier><identifier>DOI: 10.4103/0019-509X.175604</identifier><identifier>PMID: 26837979</identifier><language>eng</language><publisher>India: Medknow Publications and Media Pvt. Ltd</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols ; Bridged-Ring Compounds - administration & dosage ; Care and treatment ; Chemotherapy ; Disease-Free Survival ; Diterpenes ; Dosage and administration ; Female ; Fluorouracil - administration & dosage ; Humans ; Induction Chemotherapy ; Male ; Methods ; Middle Aged ; Mouth - drug effects ; Mouth - pathology ; Mouth cancer ; Mouth Neoplasms - drug therapy ; Mouth Neoplasms - pathology ; Paclitaxel - administration & dosage ; Platinum - administration & dosage ; Platinum compounds ; Remission Induction ; Taxoids - administration & dosage</subject><ispartof>Indian journal of cancer, 2015-01, Vol.52 (1), p.70</ispartof><rights>COPYRIGHT 2015 Medknow Publications and Media Pvt. Ltd.</rights><rights>Copyright Medknow Publications & Media Pvt Ltd Jan-Mar 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-d8ea34d0533befea313ace390d885ee5199b91febf38efc6ff29038d665fe8fc3</citedby><cites>FETCH-LOGICAL-c463t-d8ea34d0533befea313ace390d885ee5199b91febf38efc6ff29038d665fe8fc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4022,27922,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26837979$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Noronha, V</creatorcontrib><creatorcontrib>Patil, V</creatorcontrib><creatorcontrib>Joshi, A</creatorcontrib><creatorcontrib>Muddu, V</creatorcontrib><creatorcontrib>Bhattacharjee, A</creatorcontrib><creatorcontrib>Juvekar, S</creatorcontrib><creatorcontrib>Arya, S</creatorcontrib><creatorcontrib>Chaturvedi, P</creatorcontrib><creatorcontrib>Chaukar, D</creatorcontrib><creatorcontrib>Pai, P S</creatorcontrib><creatorcontrib>Dcruz, A K</creatorcontrib><creatorcontrib>Prabhash, K</creatorcontrib><title>Is taxane/platinum/5 fluorouracil superior to taxane/platinum alone and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers?</title><title>Indian journal of cancer</title><addtitle>Indian J Cancer</addtitle><description>Cisplatin and 5 fluorouracil drug combination is inferior to the combination of taxane with these 2 drugs. However, often in clinical practice at our center giving TPF (docetaxel, cisplatin, 5 fluorouracil) is difficult in view of logistics and tolerance issues. In such a scenario, we prefer to use the 2 drugs combination of platinum and taxane. However, no study has addressed whether a 2 drugs combination, which includes taxane is inferior to the 3 drugs combination and which the taxane of choice is in the 2 drugs combination of taxane and platinum.
This is a retrospective analysis of prospectively collected data of patients undergoing induction chemotherapy (IC) in oral cavity cancers from 2010 to 2012. We chose for analysis those patients who had a baseline scan done within 4 weeks of starting therapy and a follow-up scan done within 2 weeks of completion of the second cycle of IC. Response was scored in accordance with RECIST version 1.1. Chi-square analysis was done to compare response rates (RRs) between regimens.
Two hundred and forty-five patients were identified. The median age was 45 years (24-70 years), 208 (84.9%) were male patients, and 154 patients (62.9%) had primary in the Buccal mucosa. The regimens received were TPF 22 (9%), docetaxel + cisplatin 97 (39.6%), paclitaxel + cisplatin 89 (36.3%), docetaxel + carboplatin 16 (6.5%) and paclitaxel + carboplatin 21 (8.6%). The overall RRs were complete response, partial response, stable disease and progressive disease in 4 (1.6%), 56 (22.9%), 145 (59.2%) and 40 (16.3%). The 3 drugs regimen (TPF) had 50% RR as compared to 22% RR with 2 drugs regimen (P = 0.004). Docetaxel containing regimens had 30.3% RR as compared to 17.2% RR with paclitaxel containing regimens (P = 0.094).
TPF has better RR than a 2 drugs taxane-containing regimen and docetaxel leads to a better RR than paclitaxel for IC in locally advanced oral cavity cancers.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols</subject><subject>Bridged-Ring Compounds - administration & dosage</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Disease-Free Survival</subject><subject>Diterpenes</subject><subject>Dosage and administration</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Humans</subject><subject>Induction Chemotherapy</subject><subject>Male</subject><subject>Methods</subject><subject>Middle Aged</subject><subject>Mouth - drug effects</subject><subject>Mouth - pathology</subject><subject>Mouth cancer</subject><subject>Mouth Neoplasms - drug therapy</subject><subject>Mouth Neoplasms - pathology</subject><subject>Paclitaxel - administration & dosage</subject><subject>Platinum - administration & dosage</subject><subject>Platinum compounds</subject><subject>Remission Induction</subject><subject>Taxoids - administration & dosage</subject><issn>0019-509X</issn><issn>1998-4774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptklFrHCEUhaW0NNtt3_tUhELfZldHZ0afSghNGwj0pYW-Da5eswZnnKoTun-ovzMOm6ZNWRSvXL-jeDgIvaVkwylhW0KorBoif2xo17SEP0MrKqWoeNfx52j1eHyGXqV0S0jNai5eorO6FayTnVyh31cJZ_VLjbCdvMpunIdtg62fQwxzVNp5nOYJogsR5_A_ipUPI2A1GmwCpLJoKAh4nOM8THhS2rtjw41lmllnF0ac9xDVdMC23OqDVt4fsDJ3atRgcIjKY63uXD6UUloxfXyNXljlE7x5qGv0_fLTt4sv1fXXz1cX59eV5i3LlRGgGDekYWwHtuwpUxqYJEaIBqAp5uwktbCzTIDVrbW1JEyYtm0sCKvZGr0_3jvF8HOGlPvbYsNYnuxp19GOU9byv9SN8tC70YZcrBpc0v0553XXCFnANapOUDcwlr8vtllX2k_4zQm-DAOD0ycFH_4R7EH5vE_Bz4vF6SlIjqCOIaUItp-iG1Q89JT0S5D6JSn9kpT-GKQiefdgxLwbwDwK_iSH3QPt6MWz</recordid><startdate>201501</startdate><enddate>201501</enddate><creator>Noronha, V</creator><creator>Patil, V</creator><creator>Joshi, A</creator><creator>Muddu, V</creator><creator>Bhattacharjee, A</creator><creator>Juvekar, S</creator><creator>Arya, S</creator><creator>Chaturvedi, P</creator><creator>Chaukar, D</creator><creator>Pai, P S</creator><creator>Dcruz, A K</creator><creator>Prabhash, K</creator><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications & Media Pvt. Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201501</creationdate><title>Is taxane/platinum/5 fluorouracil superior to taxane/platinum alone and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers?</title><author>Noronha, V ; Patil, V ; Joshi, A ; Muddu, V ; Bhattacharjee, A ; Juvekar, S ; Arya, S ; Chaturvedi, P ; Chaukar, D ; Pai, P S ; Dcruz, A K ; Prabhash, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-d8ea34d0533befea313ace390d885ee5199b91febf38efc6ff29038d665fe8fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols</topic><topic>Bridged-Ring Compounds - administration & dosage</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Disease-Free Survival</topic><topic>Diterpenes</topic><topic>Dosage and administration</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Humans</topic><topic>Induction Chemotherapy</topic><topic>Male</topic><topic>Methods</topic><topic>Middle Aged</topic><topic>Mouth - drug effects</topic><topic>Mouth - pathology</topic><topic>Mouth cancer</topic><topic>Mouth Neoplasms - drug therapy</topic><topic>Mouth Neoplasms - pathology</topic><topic>Paclitaxel - administration & dosage</topic><topic>Platinum - administration & dosage</topic><topic>Platinum compounds</topic><topic>Remission Induction</topic><topic>Taxoids - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Noronha, V</creatorcontrib><creatorcontrib>Patil, V</creatorcontrib><creatorcontrib>Joshi, A</creatorcontrib><creatorcontrib>Muddu, V</creatorcontrib><creatorcontrib>Bhattacharjee, A</creatorcontrib><creatorcontrib>Juvekar, S</creatorcontrib><creatorcontrib>Arya, S</creatorcontrib><creatorcontrib>Chaturvedi, P</creatorcontrib><creatorcontrib>Chaukar, D</creatorcontrib><creatorcontrib>Pai, P S</creatorcontrib><creatorcontrib>Dcruz, A K</creatorcontrib><creatorcontrib>Prabhash, K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Indian journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Noronha, V</au><au>Patil, V</au><au>Joshi, A</au><au>Muddu, V</au><au>Bhattacharjee, A</au><au>Juvekar, S</au><au>Arya, S</au><au>Chaturvedi, P</au><au>Chaukar, D</au><au>Pai, P S</au><au>Dcruz, A K</au><au>Prabhash, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is taxane/platinum/5 fluorouracil superior to taxane/platinum alone and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers?</atitle><jtitle>Indian journal of cancer</jtitle><addtitle>Indian J Cancer</addtitle><date>2015-01</date><risdate>2015</risdate><volume>52</volume><issue>1</issue><spage>70</spage><pages>70-</pages><issn>0019-509X</issn><eissn>1998-4774</eissn><abstract>Cisplatin and 5 fluorouracil drug combination is inferior to the combination of taxane with these 2 drugs. However, often in clinical practice at our center giving TPF (docetaxel, cisplatin, 5 fluorouracil) is difficult in view of logistics and tolerance issues. In such a scenario, we prefer to use the 2 drugs combination of platinum and taxane. However, no study has addressed whether a 2 drugs combination, which includes taxane is inferior to the 3 drugs combination and which the taxane of choice is in the 2 drugs combination of taxane and platinum.
This is a retrospective analysis of prospectively collected data of patients undergoing induction chemotherapy (IC) in oral cavity cancers from 2010 to 2012. We chose for analysis those patients who had a baseline scan done within 4 weeks of starting therapy and a follow-up scan done within 2 weeks of completion of the second cycle of IC. Response was scored in accordance with RECIST version 1.1. Chi-square analysis was done to compare response rates (RRs) between regimens.
Two hundred and forty-five patients were identified. The median age was 45 years (24-70 years), 208 (84.9%) were male patients, and 154 patients (62.9%) had primary in the Buccal mucosa. The regimens received were TPF 22 (9%), docetaxel + cisplatin 97 (39.6%), paclitaxel + cisplatin 89 (36.3%), docetaxel + carboplatin 16 (6.5%) and paclitaxel + carboplatin 21 (8.6%). The overall RRs were complete response, partial response, stable disease and progressive disease in 4 (1.6%), 56 (22.9%), 145 (59.2%) and 40 (16.3%). The 3 drugs regimen (TPF) had 50% RR as compared to 22% RR with 2 drugs regimen (P = 0.004). Docetaxel containing regimens had 30.3% RR as compared to 17.2% RR with paclitaxel containing regimens (P = 0.094).
TPF has better RR than a 2 drugs taxane-containing regimen and docetaxel leads to a better RR than paclitaxel for IC in locally advanced oral cavity cancers.</abstract><cop>India</cop><pub>Medknow Publications and Media Pvt. Ltd</pub><pmid>26837979</pmid><doi>10.4103/0019-509X.175604</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0019-509X |
| ispartof | Indian journal of cancer, 2015-01, Vol.52 (1), p.70 |
| issn | 0019-509X 1998-4774 |
| language | eng |
| recordid | cdi_proquest_journals_1771741364 |
| source | MEDLINE; Medknow Open Access Medical Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Bioline International |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols Bridged-Ring Compounds - administration & dosage Care and treatment Chemotherapy Disease-Free Survival Diterpenes Dosage and administration Female Fluorouracil - administration & dosage Humans Induction Chemotherapy Male Methods Middle Aged Mouth - drug effects Mouth - pathology Mouth cancer Mouth Neoplasms - drug therapy Mouth Neoplasms - pathology Paclitaxel - administration & dosage Platinum - administration & dosage Platinum compounds Remission Induction Taxoids - administration & dosage |
| title | Is taxane/platinum/5 fluorouracil superior to taxane/platinum alone and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T10%3A27%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20taxane/platinum/5%20fluorouracil%20superior%20to%20taxane/platinum%20alone%20and%20does%20docetaxel%20trump%20paclitaxel%20in%20induction%20therapy%20for%20locally%20advanced%20oral%20cavity%20cancers?&rft.jtitle=Indian%20journal%20of%20cancer&rft.au=Noronha,%20V&rft.date=2015-01&rft.volume=52&rft.issue=1&rft.spage=70&rft.pages=70-&rft.issn=0019-509X&rft.eissn=1998-4774&rft_id=info:doi/10.4103/0019-509X.175604&rft_dat=%3Cgale_proqu%3EA442758941%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1771741364&rft_id=info:pmid/26837979&rft_galeid=A442758941&rfr_iscdi=true |